Table 2 Clinical characteristics of patients eligible for each biologic therapy
Eligibility | |||||
|---|---|---|---|---|---|
All | Omalizumab | Mepolizumab | Reslizumab | Benralizumab | |
Demographic characteristic | (n = 128) | (n = 84) | (n = 100) | (n = 52) | (n = 68) |
Age, years, mean (range) | 53.26 (20–89) | 53.07 (20–89) | 53.87 (20–89) | 54.79 (20–89) | 53.49 (20–89) |
Gender, female, n (%) | 86 (67) | 57 (68) | 67 (67) | 33 (63) | 46 (68) |
Current inhaled corticosteroid use, n (%) | 125 (98) | 82 (98) | 98 (98) | 52 (100) | 68 (100) |
ED visit(s)/hospitalization(s)a, n | 52 | 35 | 38 | 24 | 29 |
% predicted FEV1, mean (SD) | 70 (19) | 73 (18) | 67 (18) | 70 (18) | 69 (17) |
≥ 150 eo/µL, n (%) | 100 (78) | 68 (81) | 100 (100) | 52 (100) | 68 (100) |
> 300 eo/µL, n (%) | 68 (53) | 47 (56) | 68 (68) | 52 (100) | 68 (100) |
≥ 400 eo/µL, n (%) | 52 (41) | 37 (44) | 52 (52) | 52 (100) | 52 (76) |
Total IgE, kU/L, mean (SD) | 759 (1522) | 231 (176) | 753 (1486) | 914 (1814) | 932 (1723) |